ASLAN Pharmaceuticals Limited (ASLN)
- Previous Close
0.5400 - Open
0.5242 - Bid --
- Ask --
- Day's Range
0.5013 - 0.5700 - 52 Week Range
0.3920 - 4.6900 - Volume
19,982 - Avg. Volume
1,002,880 - Market Cap (intraday)
12.214M - Beta (5Y Monthly) 1.47
- PE Ratio (TTM)
-- - EPS (TTM)
-2.7500 - Earnings Date Apr 26, 2024 - Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.50
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
aslanpharma.comRecent News: ASLN
Performance Overview: ASLN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASLN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASLN
Valuation Measures
Market Cap
12.22M
Enterprise Value
17.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.74
Price/Book (mrq)
--
Enterprise Value/Revenue
1.48
Enterprise Value/EBITDA
-0.45
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.71%
Return on Equity (ttm)
--
Revenue (ttm)
12M
Net Income Avi to Common (ttm)
-44.22M
Diluted EPS (ttm)
-2.7500
Balance Sheet and Cash Flow
Total Cash (mrq)
21.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-30.01M
Research Analysis: ASLN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell